5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase II study will be to investigate the antiangiogenic agent,
aflibercept, in combination with chemoradiation as preoperative treatment for patients with
stage II/III rectal cancer, followed by 4 months of FOLFOX6 plus aflibercept adjuvantly.